piwik-script

Intern
    Institut für Virologie und Immunbiologie

    Prof. Dr. Asisa Volz

    New vaccines against emerging zoonotic infections: From animal models to clinical evaluation
    Datum: 14.09.2022, 17:00 - 18:00 Uhr

    HZI Forum, X 0.13

    and

    via Zoom to HZI sites / Link will follow 

     

    Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third
    generation vaccine against smallpox
    and serves as a potent vector system for development of new candidate vaccines against infectious
    diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken
    cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional
    smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts
    and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment. At present, MVA
    serves as an advanced vaccine technology platform for developing new vector vaccines against infectious
    disease and cancer including emerging viruses. Previous work addressed the development of an MVA
    candidate vaccine against MERS with immunizations in animal models demonstrating the safety,
    immunogenicity and protective efficacy of MVA induced MERS CoV S antigen specific immunity. Clinical
    safety and immunogenicity of the MVA MERS S candidate vaccine was established in a first in man phase I
    clinical study. Currently, MVA MERS S is being tested in an European level collaboration for phase 1b/2a
    clinical evaluation. Recent work addressed the preclinical development of MVA vector vaccines against
    COVID 19, including the candidate vaccine MVA SARS 2 S (MVA S). Immunizations with MVA S in animal
    models demonstrated the safety, immunogenicity and protective efficacy of this vector vaccine delivering the
    native full length SARS CoV 2 S antigen. Further, MVA S entered phase 1a clinical evaluation to assess the
    clinical safety and tolerability of two administrations and two ascending dose levels in healthy adults.

    Zurück